Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Natural Products Journal, The
  4. Fast Track Articles
  5. Fast Track Article
image of Green Tea's EGCG: Brewing Hope in the Battle against Breast Cancer

Abstract

Breast cancer, a pervasive global malignancy, is anticipated to undergo a significant increase by 2040. Despite the conventional armamentarium of treatments including chemotherapy, radiation therapy, and surgery, the intricate landscape of breast cancer, characterized by its multifaceted surface receptors and signalling pathways, presents formidable challenges to treatment efficacy. Epigallocatechin-3-gallate (EGCG), extracted from , has emerged as a subject of interest due to its robust antioxidative properties stemming from its chemical structure. EGCG exerts its effects on pivotal stages of tumour growth and proliferation by modulating key signalling pathways such as MAPK, PI3K, NFkB, and ERK1/2 influencing apoptosis and cell cycle regulation. Clinical trials have provided insights into EGCG's potential impact on breast cancer such as mammographic density and pharmacokinetics, indicating its potential as a potent therapeutic agent. Moreover, when administered with conventional chemotherapy, EGCG demonstrates synergistic effects, enhancing therapeutic outcomes. Nevertheless, further research is warranted to validate the safety and efficacy of EGCG in breast cancer prevention and treatment.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/npj/10.2174/0122103155349614241215045420
2025-01-21
2025-04-24

  • From This Site

    /content/journals/npj/10.2174/0122103155349614241215045420
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Lazzeroni M. Guerrieri-Gonzaga A. Gandini S. Johansson H. Serrano D. Cazzaniga M. Aristarco V. Macis D. Mora S. Caldarella P. Pagani G. Pruneri G. Riva A. Petrangolini G. Morazzoni P. DeCensi A. Bonanni B. A presurgical study of lecithin formulation of green tea extract in women with early breast cancer. Cancer Prev. Res. 2017 10 6 363 370 10.1158/1940‑6207.CAPR‑16‑0298 28400479
    [Google Scholar]
  2. Cabrera C. Artacho R. Giménez R. Beneficial effects of green tea--A review. J. Am. Coll. Nutr. 2006 25 2 79 99 10.1080/07315724.2006.10719518 16582024
    [Google Scholar]
  3. Yang C.S. Wang H. Mechanistic issues concerning cancer prevention by tea catechins. Mol. Nutr. Food Res. 2011 55 6 819 831 10.1002/mnfr.201100036 21538856
    [Google Scholar]
  4. Rahmani A.H. Al shabrmi F.M. Allemailem K.S. Aly S.M. Khan M.A. Implications of green tea and its constituents in the prevention of cancer via the modulation of cell signalling pathway. BioMed Res. Int. 2015 2015 1 12 10.1155/2015/925640 25977926
    [Google Scholar]
  5. Graham H.N. Green tea composition, consumption, and polyphenol chemistry. Prev. Med. 1992 21 3 334 350 10.1016/0091‑7435(92)90041‑F 1614995
    [Google Scholar]
  6. Chen B.H. Hsieh C.H. Tsai S.Y. Wang C.Y. Wang C.C. Anticancer effects of epigallocatechin-3-gallate nanoemulsion on lung cancer cells through the activation of AMP-activated protein kinase signaling pathway. Sci. Rep. 2020 10 1 5163 10.1038/s41598‑020‑62136‑2 32198390
    [Google Scholar]
  7. Mocanu M.M. Ganea C. Georgescu L. Váradi T. Shrestha D. Baran I. Katona E. Nagy P. Szöllősi J. Epigallocatechin 3-O-gallate induces 67 kDa laminin receptor-mediated cell death accompanied by downregulation of ErbB proteins and altered lipid raft clustering in mammary and epidermoid carcinoma cells. J. Nat. Prod. 2014 77 2 250 257 10.1021/np4007712 24456004
    [Google Scholar]
  8. Yang C.S. Wang H. Li G.X. Yang Z. Guan F. Jin H. Cancer prevention by tea: Evidence from laboratory studies. Pharmacol. Res. 2011 64 2 113 122 10.1016/j.phrs.2011.03.001 21397027
    [Google Scholar]
  9. Fan F.Y. Sang L.X. Jiang M. Catechins and their therapeutic benefits to inflammatory bowel disease. Molecules 2017 22 3 484 10.3390/molecules22030484 28335502
    [Google Scholar]
  10. Yuan J.M. Sun C. Butler L.M. Tea and cancer prevention: Epidemiological studies. Pharmacol. Res. 2011 64 2 123 135 10.1016/j.phrs.2011.03.002 21419224
    [Google Scholar]
  11. Anand P. Kunnumakara A.B. Sundaram C. Harikumar K.B. Tharakan S.T. Lai O.S. Sung B. Aggarwal B.B. Cancer is a preventable disease that requires major lifestyle changes. Pharm. Res. 2008 25 9 2097 2116 10.1007/s11095‑008‑9661‑9 18626751
    [Google Scholar]
  12. Brody H. Prostate cancer. Nature 2015 528 7582 S117 10.1038/528S117a 26672779
    [Google Scholar]
  13. Arnold M. Morgan E. Rumgay H. Mafra A. Singh D. Laversanne M. Vignat J. Gralow J.R. Cardoso F. Siesling S. Soerjomataram I. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast 2022 66 15 23 10.1016/j.breast.2022.08.010 36084384
    [Google Scholar]
  14. Baselga J. Norton L. Focus on breast cancer. Cancer Cell 2002 1 4 319 322 10.1016/S1535‑6108(02)00066‑1 12086846
    [Google Scholar]
  15. Burstein H.J. Temin S. Anderson H. Buchholz T.A. Davidson N.E. Gelmon K.E. Giordano S.H. Hudis C.A. Rowden D. Solky A.J. Stearns V. Winer E.P. Griggs J.J. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused update. J. Clin. Oncol. 2014 32 21 2255 2269 10.1200/JCO.2013.54.2258 24868023
    [Google Scholar]
  16. Chen D. Dou Q.P. Tea polyphenols and their roles in cancer prevention and chemotherapy. Int. J. Mol. Sci. 2008 9 7 1196 1206 10.3390/ijms9071196 19325799
    [Google Scholar]
  17. Almatroodi S.A. Almatroudi A. Khan A.A. Alhumaydhi F.A. Alsahli M.A. Rahmani A.H. Potential therapeutic targets of epigallocatechin gallate (EGCG), the most abundant catechin in green tea, and its role in the therapy of various types of cancer. Molecules 2020 25 14 3146 10.3390/molecules25143146 32660101
    [Google Scholar]
  18. Kedhari Sundaram M Haque S Somvanshi P Bhardwaj T Hussain A. Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways. 3 Biotech 2020 10 11 484
    [Google Scholar]
  19. Kim H.S. Quon M.J. Kim J. New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate. Redox Biol. 2014 2 187 195 10.1016/j.redox.2013.12.022 24494192
    [Google Scholar]
  20. Johnson J.J. Bailey H.H. Mukhtar H. Green tea polyphenols for prostate cancer chemoprevention: A translational perspective. Phytomedicine 2010 17 1 3 13 10.1016/j.phymed.2009.09.011 19959000
    [Google Scholar]
  21. Zhang L. Wen J.X. Hai L. Wang Y.F. Yan L. Gao W.H. Hu Z.D. Wang Y.J. Preventive and therapeutic effects of green tea on lung cancer: A narrative review of evidence from clinical and basic research. J. Thorac. Dis. 2022 14 12 5029 5038 10.21037/jtd‑22‑1791 36647481
    [Google Scholar]
  22. Thangapazham R.L. Singh A.K. Sharma A. Warren J. Gaddipati J.P. Maheshwari R.K. Cancer preventive activities of tea catechins. Molecules 2016 21 12 1679 10.3390/molecules21121679 27941682
    [Google Scholar]
  23. Kanlaya R. Thongboonkerd V. Protective effects of epigallocatechin-3-gallate from green tea in various kidney diseases. Adv. Nutr. 2019 10 1 112 121 10.1093/advances/nmy077 30615092
    [Google Scholar]
  24. Kassouri C. Rodriguez Torres S. Gonzalez Suarez N. Duhamel S. Annabi B. EGCG prevents the transcriptional reprogramming of an inflammatory and immune-suppressive molecular signature in macrophage-like differentiated human HL60 promyelocytic leukemia cells. Cancers 2022 14 20 5065 10.3390/cancers14205065 36291849
    [Google Scholar]
  25. Romano A. Martel F. The role of EGCG in breast cancer prevention and therapy. Mini Rev. Med. Chem. 2021 21 7 883 898 10.2174/18755607MTEyrMzcq0 33319659
    [Google Scholar]
  26. Sun W. Yang Y. Wang C. Liu M. Wang J. Qiao S. Jiang P. Sun C. Jiang S. Epigallocatechin-3-gallate at the nanoscale: A new strategy for cancer treatment. Pharm. Biol. 2024 62 1 676 690 10.1080/13880209.2024.2406779 39345207
    [Google Scholar]
  27. Chavva S.R. Deshmukh S.K. Kanchanapally R. Tyagi N. Coym J.W. Singh A.P. Singh S. Epigallocatechin gallate-gold nanoparticles exhibit superior antitumor activity compared to conventional gold nanoparticles: potential synergistic interactions. Nanomaterials 2019 9 3 396 10.3390/nano9030396 30857226
    [Google Scholar]
  28. Coughlin S.S. Ekwueme D.U. Breast cancer as a global health concern. Cancer Epidemiol. 2009 33 5 315 318 10.1016/j.canep.2009.10.003 19896917
    [Google Scholar]
  29. Saeed M. Naveed M. Arif M. Kakar M.U. Manzoor R. Abd El-Hack M.E. Alagawany M. Tiwari R. Khandia R. Munjal A. Karthik K. Dhama K. Iqbal H.M.N. Dadar M. Sun C. Green tea (Camellia sinensis) and l-theanine: Medicinal values and beneficial applications in humans—A comprehensive review. Biomed. Pharmacother. 2017 95 1260 1275 10.1016/j.biopha.2017.09.024 28938517
    [Google Scholar]
  30. Wong M. Sirisena S. Ng K. Phytochemical profile of differently processed tea: A review. J. Food Sci. 2022 87 5 1925 1942 10.1111/1750‑3841.16137 35368105
    [Google Scholar]
  31. Rashidi B. Malekzadeh M. Goodarzi M. Masoudifar A. Mirzaei H. Green tea and its anti-angiogenesis effects. Biomed. Pharmacother. 2017 89 949 956 10.1016/j.biopha.2017.01.161 28292023
    [Google Scholar]
  32. Lee J.E. Lee B.J. Chung J.O. Hwang J.A. Lee S.J. Lee C.H. Hong Y.S. Geographical and climatic dependencies of green tea (Camellia sinensis) metabolites: A (1)H NMR-based metabolomics study. J. Agric. Food Chem. 2010 58 19 10582 10589 10.1021/jf102415m 20828156
    [Google Scholar]
  33. Weisburger J.H. Chung F.L. Mechanisms of chronic disease causation by nutritional factors and tobacco products and their prevention by tea polyphenols. Food Chem. Toxicol. 2002 40 8 1145 1154 10.1016/S0278‑6915(02)00044‑3 12067577
    [Google Scholar]
  34. Dufresne C.J. Farnworth E.R. A review of latest research findings on the health promotion properties of tea. J. Nutr. Biochem. 2001 12 7 404 421 10.1016/S0955‑2863(01)00155‑3 11448616
    [Google Scholar]
  35. Sumpio B.E. Cordova A.C. Berke-Schlessel D.W. Qin F. Chen Q.H. Green tea, the “Asian paradox,” and cardiovascular disease. J. Am. Coll. Surg. 2006 202 5 813 825 10.1016/j.jamcollsurg.2006.01.018 16648021
    [Google Scholar]
  36. Fon Sing M. Yang W.S. Gao S. Gao J. Xiang Y.B. Epidemiological studies of the association between tea drinking and primary liver cancer. Eur. J. Cancer Prev. 2011 20 3 157 165 10.1097/CEJ.0b013e3283447497 21403523
    [Google Scholar]
  37. Fujiki H. Watanabe T. Sueoka E. Rawangkan A. Suganuma M. Cancer prevention with green tea and its principal constituent, EGCG: From early investigations to current focus on human cancer stem cells. Mol. Cells 2018 41 2 73 82 29429153
    [Google Scholar]
  38. Jacob S.A. Khan T.M. Lee L.H. The effect of green tea consumption on prostate cancer risk and progression: A systematic review. Nutr. Cancer 2017 69 3 353 364 10.1080/01635581.2017.1285037 28287319
    [Google Scholar]
  39. Mann C.D. Neal C.P. Garcea G. Manson M.M. Dennison A.R. Berry D.P. Phytochemicals as potential chemopreventive and chemotherapeutic agents in hepatocarcinogenesis. Eur. J. Cancer Prev. 2009 18 1 13 25 10.1097/CEJ.0b013e3282f0c090 19077560
    [Google Scholar]
  40. Yiannakopoulou E.C. Interaction of green tea catechins with breast cancer endocrine treatment: A systematic review. Pharmacology 2014 94 5-6 245 248 10.1159/000369170 25471334
    [Google Scholar]
  41. Chikara S. Nagaprashantha L.D. Singhal J. Horne D. Awasthi S. Singhal S.S. Oxidative stress and dietary phytochemicals: Role in cancer chemoprevention and treatment. Cancer Lett. 2018 413 122 134 10.1016/j.canlet.2017.11.002 29113871
    [Google Scholar]
  42. Gianfredi V. Nucci D. Vannini S. Villarini M. Moretti M. in vitro biological effects of sulforaphane (SFN), epigallocatechin-3-gallate (EGCG), and curcumin on breast cancer cells: A systematic review of the literature. Nutr. Cancer 2017 69 7 969 978 10.1080/01635581.2017.1359322 28872903
    [Google Scholar]
  43. Sur S. Panda C.K. Molecular aspects of cancer chemopreventive and therapeutic efficacies of tea and tea polyphenols. Nutrition 2017 43-44 8 15 10.1016/j.nut.2017.06.006 28935149
    [Google Scholar]
  44. Gianfredi V. Vannini S. Moretti M. Villarini M. Bragazzi N.L. Izzotti A. Nucci D. Sulforaphane and epigallocatechin gallate restore estrogen receptor expression by modulating epigenetic events in the breast cancer cell line MDA-MB-231: A systematic review and meta-analysis. J. Nutrigenet. Nutrigenomics 2017 10 3-4 126 135 29040973
    [Google Scholar]
  45. Farhan M. Green tea catechins: Nature’s way of preventing and treating cancer. Int. J. Mol. Sci. 2022 23 18 10713 10.3390/ijms231810713 36142616
    [Google Scholar]
  46. Chong S.Y. Chiang H.Y. Chen T.H. Liang Y.J. Lo Y.C. Green tea extract promotes DNA repair in a yeast model. Sci. Rep. 2019 9 1 3842 10.1038/s41598‑019‑39082‑9 30846712
    [Google Scholar]
  47. Frolinger T. Herman F. Sharma A. Sims S. Wang J. Pasinetti G.M. Epigenetic modifications by polyphenolic compounds alter gene expression in the hippocampus. Biol. Open 2018 7 10 bio.035196 10.1242/bio.035196 29970476
    [Google Scholar]
  48. Yaskolka MA Keller M Hoffmann A Rinott E Tsaban G The effect of polyphenols on DNA methylation-assessed biological age attenuation: The DIRECT PLUS randomized controlled trial. BMC Med. 2023 21 1 364 10.1186/s12916‑023‑03067‑3
    [Google Scholar]
  49. Rajendran P. Abdelsalam S.A. Renu K. Veeraraghavan V. Ben Ammar R. Ahmed E.A. Polyphenols as potent epigenetics agents for cancer. Int. J. Mol. Sci. 2022 23 19 11712 10.3390/ijms231911712 36233012
    [Google Scholar]
  50. Botten D. Fugallo G. Fraternali F. Molteni C. Structural properties of green tea catechins. J. Phys. Chem. B 2015 119 40 12860 12867 10.1021/acs.jpcb.5b08737 26369298
    [Google Scholar]
  51. Cai Y.Z. Mei Sun Jie Xing Luo Q. Corke H. Structure–radical scavenging activity relationships of phenolic compounds from traditional Chinese medicinal plants. Life Sci. 2006 78 25 2872 2888 10.1016/j.lfs.2005.11.004 16325868
    [Google Scholar]
  52. Potenza M.A. Iacobazzi D. Sgarra L. Montagnani M. The intrinsic virtues of EGCG, an extremely good cell guardian, on prevention and treatment of diabesity complications. Molecules 2020 25 13 3061 10.3390/molecules25133061 32635492
    [Google Scholar]
  53. Marín V. Burgos V. Pérez R. Maria D.A. Pardi P. Paz C. The potential role of epigallocatechin-3-gallate (EGCG) in breast cancer treatment. Int. J. Mol. Sci. 2023 24 13 10737 10.3390/ijms241310737 37445915
    [Google Scholar]
  54. Yang C.S. Wang X. Lu G. Picinich S.C. Cancer prevention by tea: Animal studies, molecular mechanisms and human relevance. Nat. Rev. Cancer 2009 9 6 429 439 10.1038/nrc2641 19472429
    [Google Scholar]
  55. Wang R. Zhou W. Jiang X. Reaction kinetics of degradation and epimerization of epigallocatechin gallate (EGCG) in aqueous system over a wide temperature range. J. Agric. Food Chem. 2008 56 8 2694 2701 10.1021/jf0730338 18361498
    [Google Scholar]
  56. Zhu Q.Y. Hackman R.M. Ensunsa J.L. Holt R.R. Keen C.L. Antioxidative activities of oolong tea. J. Agric. Food Chem. 2002 50 23 6929 6934 10.1021/jf0206163 12405799
    [Google Scholar]
  57. Hara K. Ohara M. Hayashi I. Hino T. Nishimura R. Iwasaki Y. Ogawa T. Ohyama Y. Sugiyama M. Amano H. The green tea polyphenol (−)‐epigallocatechin gallate precipitates salivary proteins including alpha‐amylase: Biochemical implications for oral health. Eur. J. Oral Sci. 2012 120 2 132 139 10.1111/j.1600‑0722.2012.00947.x 22409219
    [Google Scholar]
  58. Zeng L. Yan J. Luo L. Ma M. Zhu H. Preparation and characterization of (−)-Epigallocatechin-3-gallate (EGCG)-loaded nanoparticles and their inhibitory effects on Human breast cancer MCF-7 cells. Sci. Rep. 2017 7 1 45521 10.1038/srep45521 28349962
    [Google Scholar]
  59. Gan R.Y. Li H.B. Sui Z.Q. Corke H. Absorption, metabolism, anti-cancer effect and molecular targets of epigallocatechin gallate (EGCG): An updated review. Crit. Rev. Food Sci. Nutr. 2018 58 6 924 941 10.1080/10408398.2016.1231168 27645804
    [Google Scholar]
  60. Nakagawa K. Miyazawa T. Chemiluminescence-high-performance liquid chromatographic determination of tea catechin, (-)-epigallocatechin 3-gallate, at picomole levels in rat and human plasma. Anal. Biochem. 1997 248 1 41 49 10.1006/abio.1997.2098 9177723
    [Google Scholar]
  61. Schröder L. Marahrens P. Koch J.G. Heidegger H. Vilsmeier T. Phan-Brehm T. Hofmann S. Mahner S. Jeschke U. Richter D.U. Effects of green tea, matcha tea and their components epigallocatechin gallate and quercetin on MCF‑7 and MDA-MB-231 breast carcinoma cells. Oncol. Rep. 2019 41 1 387 396 30320348
    [Google Scholar]
  62. Takagaki A. Nanjo F. Metabolism of (-)-epigallocatechin gallate by rat intestinal flora. J. Agric. Food Chem. 2010 58 2 1313 1321 10.1021/jf903375s 20043675
    [Google Scholar]
  63. Sang S. Lambert J.D. Ho C.T. Yang C.S. The chemistry and biotransformation of tea constituents. Pharmacol. Res. 2011 64 2 87 99 10.1016/j.phrs.2011.02.007 21371557
    [Google Scholar]
  64. Bray F. Ferlay J. Soerjomataram I. Siegel R.L. Torre L.A. Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018 68 6 394 424 10.3322/caac.21492 30207593
    [Google Scholar]
  65. Narod S.A. Foulkes W.D. BRCA1 and BRCA2: 1994 and beyond. Nat. Rev. Cancer 2004 4 9 665 676 10.1038/nrc1431 15343273
    [Google Scholar]
  66. Tutt A. Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol. Med. 2002 8 12 571 576 10.1016/S1471‑4914(02)02434‑6 12470990
    [Google Scholar]
  67. Vivanco I. Sawyers C.L. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer. Nat. Rev. Cancer 2002 2 7 489 501 10.1038/nrc839 12094235
    [Google Scholar]
  68. Kessenbrock K. Plaks V. Werb Z. Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell 2010 141 1 52 67 10.1016/j.cell.2010.03.015 20371345
    [Google Scholar]
  69. Thiery J.P. Acloque H. Huang R.Y.J. Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009 139 5 871 890 10.1016/j.cell.2009.11.007 19945376
    [Google Scholar]
  70. Joyce J.A. Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009 9 4 239 252 10.1038/nrc2618 19279573
    [Google Scholar]
  71. Mukherjee S. Ghosh S. Das D.K. Chakraborty P. Choudhury S. Gupta P. Adhikary A. Dey S. Chattopadhyay S. Gold-conjugated green tea nanoparticles for enhanced anti-tumor activities and hepatoprotection — Synthesis, characterization and in vitro evaluation. J. Nutr. Biochem. 2015 26 11 1283 1297 10.1016/j.jnutbio.2015.06.003 26310506
    [Google Scholar]
  72. Kavanagh K.T. Hafer L.J. Kim D.W. Mann K.K. Sherr D.H. Rogers A.E. Sonenshein G.E. Green tea extracts decrease carcinogen‐induced mammary tumor burden in rats and rate of breast cancer cell proliferation in culture. J. Cell. Biochem. 2001 82 3 387 398 10.1002/jcb.1164 11500915
    [Google Scholar]
  73. Ávila-Gálvez M.Á. Giménez-Bastida J.A. Espín J.C. González-Sarrías A. Dietary phenolics against breast cancer. A critical evidence-based review and future perspectives. Int. J. Mol. Sci. 2020 21 16 5718 10.3390/ijms21165718 32784973
    [Google Scholar]
  74. Hong O.Y. Noh E.M. Jang H.Y. Lee Y.R. Lee B.K. Jung S.H. Kim J.S. Youn H.J. Epigallocatechin gallate inhibits the growth of MDA-MB-231 breast cancer cells via inactivation of the β-catenin signaling pathway. Oncol. Lett. 2017 14 1 441 446 10.3892/ol.2017.6108 28693189
    [Google Scholar]
  75. Luo H.Q. Xu M. Zhong W.T. Cui Z.Y. Liu F.M. Zhou K.Y. Li X.Y. EGCG decreases the expression of HIF-1α and VEGF and cell growth in MCF-7 breast cancer cells. J. Balkan Union Oncol. 2014 19 2 435 439 24965403
    [Google Scholar]
  76. Zhao H. Zhu W. Zhao X. Li X. Zhou Z. Zheng M. Meng X. Kong L. Zhang S. He D. Xing L. Yu J. Efficacy of epigallocatechin-3-gallate in preventing dermatitis in patients with breast cancer receiving postoperative radiotherapy. JAMA Dermatol. 2022 158 7 779 786 10.1001/jamadermatol.2022.1736 35648426
    [Google Scholar]
  77. Bimonte S. Cascella M. Barbieri A. Arra C. Cuomo A. Shining a light on the effects of the combination of (–)-epigallocatechin-3-gallate and tapentadol on the growth of human triple-negative breast cancer cells. In Vivo 2019 33 5 1463 1468 10.21873/invivo.11625 31471393
    [Google Scholar]
  78. Steed K.L. Jordan H.R. Tollefsbol T.O. SAHA and EGCG promote apoptosis in triple-negative breast cancer cells, possibly through the modulation of cIAP2. Anticancer Res. 2020 40 1 9 26 10.21873/anticanres.13922 31892549
    [Google Scholar]
  79. Baker K.M. Bauer A.C. Green tea catechin, EGCG, suppresses PCB 102-induced proliferation in estrogen-sensitive breast cancer cells. Int. J. Breast Cancer 2015 2015 1 7 10.1155/2015/163591 26783468
    [Google Scholar]
  80. Braicu C. Gherman C.D. Irimie A. Berindan-Neagoe I. Epigallocatechin-3-Gallate (EGCG) inhibits cell proliferation and migratory behaviour of triple negative breast cancer cells. J. Nanosci. Nanotechnol. 2013 13 1 632 637 10.1166/jnn.2013.6882 23646788
    [Google Scholar]
  81. Zhang T. Li N. Wang R. Sun Y. He X. Lu X. Chu L. Sun K. Enhanced therapeutic efficacy of doxorubicin against multidrug-resistant breast cancer with reduced cardiotoxicity. Drug Deliv. 2023 30 1 2189118 10.1080/10717544.2023.2189118 36919676
    [Google Scholar]
  82. Wang Z. Erb B. Receptors and cancer. Methods Mol. Biol. 2017 1652 3 35 10.1007/978‑1‑4939‑7219‑7_1 28791631
    [Google Scholar]
  83. Goodin M.G. Fertuck K.C. Zacharewski T.R. Rosengren R.J. Estrogen receptor-mediated actions of polyphenolic catechins in vivo and in vitro. Toxicol. Sci. 2002 69 2 354 361 10.1093/toxsci/69.2.354 12377984
    [Google Scholar]
  84. Hsu Y.C. Liou Y.M. The anti‐cancer effects of (−)‐Epigalocathine‐3‐gallate on the signaling pathways associated with membrane receptors in MCF‐7 cells. J. Cell. Physiol. 2011 226 10 2721 2730 10.1002/jcp.22623 21792929
    [Google Scholar]
  85. Khan N. Afaq F. Saleem M. Ahmad N. Mukhtar H. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res. 2006 66 5 2500 2505 10.1158/0008‑5472.CAN‑05‑3636 16510563
    [Google Scholar]
  86. Singh T. Vaid M. Katiyar S.K. EGCG, a polyphenol from green tea, inhibits cytokine-induced MMP-2 expression and activity in human prostate carcinoma cells. J. Nutr. 2011 141 2 190 196
    [Google Scholar]
  87. Fang M.Z. Wang Y. Ai N. Hou Z. Tea polyphenol EGCG inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 2003 63 22 7563 7570 14633667
    [Google Scholar]
  88. Pan X. Zhao B. Song Z. Han S. Wang M. Estrogen receptor-α36 is involved in epigallocatechin-3-gallate induced growth inhibition of ER-negative breast cancer stem/progenitor cells. J. Pharmacol. Sci. 2016 130 2 85 93 10.1016/j.jphs.2015.12.003 26810571
    [Google Scholar]
  89. Wang P. Wang B. Chung S. Wu Y. Henning S.M. Vadgama J.V. Increased chemopreventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells. RSC Advances 2014 4 66 35242 35250 10.1039/C4RA06616B 25243063
    [Google Scholar]
  90. Landis-Piwowar K. Chen D. Chan T.H. Dou Q.P. Inhibition of catechol-Omicron-methyltransferase activity in human breast cancer cells enhances the biological effect of the green tea polyphenol (-)-EGCG. Oncol. Rep. 2010 24 2 563 569 20596647
    [Google Scholar]
  91. Filippi A. Picot T. Aanei C.M. Nagy P. Szöllősi J. Campos L. Ganea C. Mocanu M.M. Epigallocatechin-3- O -gallate alleviates the malignant phenotype in A-431 epidermoid and SK-BR-3 breast cancer cell lines. Int. J. Food Sci. Nutr. 2018 69 5 584 597 10.1080/09637486.2017.1401980 29157036
    [Google Scholar]
  92. Das A. Haque I. Ray P. Ghosh A. Dutta D. Quadir M. De A. Gunewardena S. Chatterjee I. Banerjee S. Weir S. Banerjee S.K. CCN5 activation by free or encapsulated EGCG is required to render triple‐negative breast cancer cell viability and tumor progression. Pharmacol. Res. Perspect. 2021 9 2 e00753 10.1002/prp2.753 33745223
    [Google Scholar]
  93. Huang C.Y. Han Z. Li X. Xie H.H. Zhu S.S. Mechanism of EGCG promoting apoptosis of MCF-7 cell line in human breast cancer. Oncol. Lett. 2017 14 3 3623 3627 10.3892/ol.2017.6641 28927122
    [Google Scholar]
  94. Hallman K. Aleck K. Quigley M. Dwyer B. Lloyd V. Szmyd M. Dinda S. The regulation of steroid receptors by epigallocatechin-3-gallate in breast cancer cells. Breast Cancer (Dove Med. Press) 2017 9 365 373 10.2147/BCTT.S131334 28579831
    [Google Scholar]
  95. Balasubramanian S. Adhikary A. Green tea polyphenol epigallocatechin gallate mediated apoptosis: Role of transcription factors. Mol. Nutr. Food Res. 2008 52 6 649 661
    [Google Scholar]
  96. Hastak K. Gupta S. Ahmad N. Agarwal M.K. Agarwal M.L. Mukhtar H. Role of p53 and NF-κB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 2003 22 31 4851 4859 10.1038/sj.onc.1206708 12894226
    [Google Scholar]
  97. Moradzadeh M. Hosseini A. Erfanian S. Rezaei H. Epigallocatechin-3-gallate promotes apoptosis in human breast cancer T47D cells through down-regulation of PI3K/AKT and Telomerase. Pharmacol. Rep. 2017 69 5 924 928 10.1016/j.pharep.2017.04.008 28646740
    [Google Scholar]
  98. Zan L. Chen Q. Zhang L. Li X. Epigallocatechin gallate (EGCG) suppresses growth and tumorigenicity in breast cancer cells by downregulation of miR-25. Bioengineered 2019 10 1 374 382 10.1080/21655979.2019.1657327 31431131
    [Google Scholar]
  99. Wang K. Wang R.L. Liu J.J. Zhou J. Li X. Hu W.W. Jiang W.J. Hao N.B. The prognostic significance of hTERT overexpression in cancers. Medicine 2018 97 35 e11794 10.1097/MD.0000000000011794 30170373
    [Google Scholar]
  100. Chung S.S. Vadgama J.V. Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFκB signaling. Anticancer Res. 2015 35 1 39 46 25550533
    [Google Scholar]
  101. Fukada T. Ohtani T. Yoshida Y. Shirogane T. Nishida K. Nakajima K. Hibi M. Hirano T. STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition. EMBO J. 1998 17 22 6670 6677 10.1093/emboj/17.22.6670 9822610
    [Google Scholar]
  102. Khan N. Mukhtar H. Epigallocatechin-3-gallate and cancer: Introduction to the special issue. Mol. Nutr. Food Res. 2013 57 1 1 2
    [Google Scholar]
  103. Amado N.G. Fonseca B.F. Cerqueira D.M. Neto V.M. Abreu J.G. Flavonoids: Potential Wnt/beta-catenin signaling modulators in cancer. Life Sci. 2011 89 15-16 545 554 10.1016/j.lfs.2011.05.003 21635906
    [Google Scholar]
  104. Boras-Granic K. Wysolmerski J.J. Wnt signaling in breast organogenesis. Organogenesis 2008 4 2 116 122 10.4161/org.4.2.5858 19279723
    [Google Scholar]
  105. Sen T. Moulik S. Dutta A. Choudhury P.R. Banerji A. Das S. Roy M. Chatterjee A. Multifunctional effect of epigallocatechin-3-gallate (EGCG) in downregulation of gelatinase-A (MMP-2) in human breast cancer cell line MCF-7. Life Sci. 2009 84 7-8 194 204 10.1016/j.lfs.2008.11.018 19105967
    [Google Scholar]
  106. Crew K.D. Brown P. Greenlee H. Bevers T.B. Arun B. Hudis C. McArthur H.L. Chang J. Rimawi M. Vornik L. Cornelison T.L. Wang A. Hibshoosh H. Ahmed A. Terry M.B. Santella R.M. Lippman S.M. Hershman D.L. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev. Res. 2012 5 9 1144 1154 10.1158/1940‑6207.CAPR‑12‑0117 22827973
    [Google Scholar]
  107. Braal C.L. Hussaarts K.G.A.M. Seuren L. Oomen-de Hoop E. de Bruijn P. Buck S.A.J. Bos M.E.M.M. Thijs-Visser M.F. Zuetenhorst H.J.M. Mathijssen-van Stein D. Vastbinder M.B. van Leeuwen R.W.F. van Gelder T. Koolen S.L.W. Jager A. Mathijssen R.H.J. Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen. Breast Cancer Res. Treat. 2020 184 1 107 113 10.1007/s10549‑020‑05829‑6 32803636
    [Google Scholar]
  108. Samavat H. Ursin G. Emory T.H. Lee E. Wang R. Torkelson C.J. Dostal A.M. Swenson K. Le C.T. Yang C.S. Yu M.C. Yee D. Wu A.H. Yuan J.M. Kurzer M.S. A randomized controlled trial of green tea extract supplementation and mammographic density in postmenopausal women at increased risk of breast cancer. Cancer Prev. Res. 2017 10 12 710 718 10.1158/1940‑6207.CAPR‑17‑0187 28904061
    [Google Scholar]
  109. Zhao H. Xie P. Li X. Zhu W. Sun X. Sun X. Chen X. Xing L. Yu J. A prospective phase II trial of EGCG in treatment of acute radiation-induced esophagitis for stage III lung cancer. Radiother. Oncol. 2015 114 3 351 356 10.1016/j.radonc.2015.02.014 25769379
    [Google Scholar]
  110. Zhao H. Zhu W. Jia L. Sun X. Chen G. Zhao X. Li X. Meng X. Kong L. Xing L. Yu J. Phase I study of topical epigallocatechin-3-gallate (EGCG) in patients with breast cancer receiving adjuvant radiotherapy. Br. J. Radiol. 2016 89 1058 20150665 10.1259/bjr.20150665 26607642
    [Google Scholar]
  111. Dostal A.M. Samavat H. Bedell S. Torkelson C. Wang R. Swenson K. Le C. Wu A.H. Ursin G. Yuan J.M. Kurzer M.S. The safety of green tea extract supplementation in postmenopausal women at risk for breast cancer: Results of the minnesota green tea trial. Food Chem. Toxicol. 2015 83 26 35 10.1016/j.fct.2015.05.019 26051348
    [Google Scholar]
/content/journals/npj/10.2174/0122103155349614241215045420
Loading
Green Tea's EGCG: Brewing Hope in the Battle against Breast Cancer
Bentham Science Publishers ; https://doi.org/10.2174/0122103155349614241215045420
/content/journals/npj/10.2174/0122103155349614241215045420
/content/journals/npj/10.2174/0122103155349614241215045420
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: antioxidants ; signalling pathways ; catechins ; Adjunctive therapy ; cancer cell line ; synergistic

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test